Aspira Women's Health Inc. · OTC:AWHL

Aspira Women's Health — Investor Presentation (June 2022)

19 slides from Aspira Women's Health's investor presentation, Jun 6, 2022

  1. Slide 1: Transforming the State of Women's Gynecological Health… Starting with Ovarian Cancer

    Slide 1: Transforming the State of Women's Gynecological Health… Starting with Ovarian Cancer

    Transforming the State of Women’s Gynecological Health… Starting with Ovarian Cancer Corporate Presentation | June 2022 Nicole Sandford, President and CEO Bob Beechey, Chief Financial Officer

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    Investment Highlights Commercial Revenue-generating test for multi-modal ovarian cancer risk assessment Test FDA-cleared Proprietary technology included in clinical treatment guidelines Technologies Focused Compelling pipeline of gynecological diagnostic tools Pipeline Intellectual Strong IP and tec

  4. Slide 4: Recent Developments

    Slide 4: Recent Developments

    Recent Developments Aspira will collaborate with BioReference Laboratories, Inc., an OPKO Health company and the largest full-service specialty laboratory in the United States, to offer OVA1Plus, which includes Aspira’s FDA-cleared Ova1 and Overa ovarian cancer risk assessments. • With a leading pos

  5. Slide 5: Starting with Ovarian Cancer …

    Slide 5: Starting with Ovarian Cancer …

    Starting with Ovarian Cancer … Most Ovarian Cancer Detected at Late Stage – When It’s Most Deadly Presentation Stage I Stage II Stage III Stage IV Stage Local Pelvic Regional nodes Distant spread Incidence 15% 21% 59% 6% Five Year 92% 75% 29% 24% Survival Rate1 Ovarian Cancer Diagnosed in the Late S

  6. Slide 6: Current Standard of Care for Assessing Cancer Treatment

    Slide 6: Current Standard of Care for Assessing Cancer Treatment

    Current Standard of Care for Assessing Cancer Treatment Blood Tumor Tissue Clinical Assessment Marker Analysis Physical exam and ultrasound CA 125 (off-label) Pre-operative biopsy not ROMA™ (alternative) recommended Limitations: Subjective results and Limitations: Low sensitivity and Limitations: Hi

  7. Slide 7: A Better Blood Risk Assessment

    Slide 7: A Better Blood Risk Assessment

    A Better Blood Risk Assessment OVA products demonstrate better performance in early-stage risk detection 5% OVA risk assessment products 31% 31% substantially improve the effectiveness of clinical 95% assessment in stratifying 69% the risk of Stage 1 and Stage 2 malignancy for women with pelvic mass

  8. Slide 8: Significant Market Opportunity

    Slide 8: Significant Market Opportunity

    Significant Market Opportunity OVA products address the unmet need and represent a significant growth opportunity for Aspira. OVA1Plus Pelvic Mass – Potential Revenue Women Planned For Surgery $100M-140M TAM=300-400K OVAWatch Pelvic Mass (one time and Potential Revenue serial mass monitoring) $200-3

  9. Slide 9: Commercial Strategy

    Slide 9: Commercial Strategy

    Commercial Strategy The expansion and commercialization of our OVA products is a top priority for 2022 Commercial Strategy Focus Sales Force Optimization Targeting gynecologic specialists, Expanded Adoption and Coverage 26 full-time women’s health access via specialized sales groups and agreements p

  10. Slide 10: OVA Adoption Since Introduction of Second-Generation Test

    Slide 10: OVA Adoption Since Introduction of Second-Generation Test

    Sales Force Optimization Adoption and OVA Adoption Since Introduction of Second-Generation Test Coverage Product Expansion Platforms and Partnerships OVA volumes have increased over time even during the Covid pandemic Professional Society Support 5000 4819 4750 4553 4500 4281 OVA Test Volume 4000 38

  11. Slide 11: OVA Adoption by Physicians Continues to Improve

    Slide 11: OVA Adoption by Physicians Continues to Improve

    Sales Force Optimization Adoption and OVA Adoption by Physicians Continues to Improve Coverage Product Expansion Total Ordering Physicians Platforms and Partnerships 3500 Physician Testimonials 3000 OVA1plus™ has made a big difference in my practice because it has added more 2500 certainty to decisi

  12. Slide 12: Market Access

    Slide 12: Market Access

    Sales Force Optimization Adoption and Market Access Coverage Product Expansion Our goal is to make OVA products available to all women Platforms and Partnerships 168 Million Commercial lives covered 48 Million Medicaid lives covered Commercial coverage also includes Medicare Advantage plans ■ Covere

  13. Slide 13: OVAWatch is our third generation OVA product

    Slide 13: OVAWatch is our third generation OVA product

    Sales Force Optimization Adoption and Coverage Product Expansion Platforms and Partnerships OVAWatch is our third generation OVA product. It is a non-invasive Lab Developed Test (LDT) to be used in conjunction with clinical assessment to determine the risk of ovarian cancer for patients with an adne

  14. Slide 14: Launch Plan

    Slide 14: Launch Plan

    Sales Force Optimization Adoption and Coverage Product Expansion Platforms and Launch Plan Partnerships 05 Initial Commercial Launch 2H 2022 Targeted for second half 2022; revenue in 2023 04 Pricing/Reimbursement Cross-walk from existing reimbursement In process arrangements for OVA1Plus 03 Clinical

  15. Slide 15: Endometriosis is an Unmet Need – and Market Opportunity

    Slide 15: Endometriosis is an Unmet Need – and Market Opportunity

    Sales Force Optimization Adoption and Endometriosis is an Unmet Need – and Market Opportunity Coverage Product Expansion Platforms and Partnerships Health Cost 6-7million Burden women affected in the U.S. by Endometriosis For women diagnosed with • EndoCheck™ is our in-development Endometriosis in t

  16. Slide 16: Aspira Synergy: Phases of the Client Relationship Lifecycle

    Slide 16: Aspira Synergy: Phases of the Client Relationship Lifecycle

    Sales Force Optimization Adoption and Aspira Synergy: Phases of the Client Relationship Lifecycle Coverage Product Expansion Platforms and Partnerships Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Agreement Implementation Launch Adoption/Scale Optimization Super Group A Sales and Adoption: Revenue Drive

  17. Slide 17: Financial Performance Snapshot

    Slide 17: Financial Performance Snapshot

    Financial Performance Snapshot Q1 vs. Last Year Q1 vs. Last quarter Cash Position OVA Product Volume OVA Product Volume Cash as of March 31, 2022 INCREASED 28% INCREASED 1% $27.1M 4,819 units in Q1FY22 vs. 4,819 units in Q1FY22 vs. 3,775 units in Q1FY21 4,750 units in Q4FY21 Cash Used in Operations

  18. Slide 18: In Conclusion ... 2022 is about Focused Execution

    Slide 18: In Conclusion ... 2022 is about Focused Execution

    In Conclusion ... Our strategy is sound, the path forward is clear. 2022 is about Focused Execution Accelerated Adoption and Volume Initial Launch Development Operational Excellence 18

  19. Slide 19: Contact Information

    Slide 19: Contact Information

    Contact Information Ashley R. Robinson LifeSci Advisors, LLC arr@lifesciadvisors.com

Source: Internet Archive copy of ir.aspirawh.com

More decks from Aspira Women's Health Inc.

All 21 Aspira Women's Health decks